Wells Fargo analyst Stan Berenshteyn upgraded GoodRx to Overweight from Equal Weight with a price target of $10, up from $7.50.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx Adjusts CEO Contract and Announces Board Changes
- GoodRx Reaffirms Financial Leadership with CFO’s Renewed Contract
- GoodRx upgraded, Fisker downgraded: Wall Street’s top analyst calls
- GoodRx price target raised to $10 from $9 at Guggenheim
- GoodRx price target raised to $7.50 from $6 at Wells Fargo
